【摘要】： 移植物抗宿主病(GVHD)仍然是臨床骨髓移植治愈血液系統(tǒng)惡性疾病的主要障礙之一。供者異基因淋巴細(xì)胞的異�；罨荊VHD發(fā)生、發(fā)展的重要因素,誘導(dǎo)受者產(chǎn)生針對(duì)供者異基因主要組織相容性抗原(MHC)特異性耐受是預(yù)防GVHD、保存GVL的最佳途徑。配對(duì)免疫球蛋白樣受體(Paired immunoglobin-like receptor,PIR)是近年發(fā)現(xiàn)的主要表達(dá)在小鼠樹突狀細(xì)胞(DCs)上的免疫抑制性調(diào)節(jié)受體,包括免疫抑制性受體(PIR-B)及免疫活化性受體(PIR-A),其配體均是MHC-Ⅰ,二者與其配體的結(jié)合的水平是決定DCs免疫活化程度的重要分子標(biāo)志之一。由于DC不僅是調(diào)控體內(nèi)T細(xì)胞活化的關(guān)鍵,也是誘導(dǎo)免疫耐受的理想的靶細(xì)胞,可以直接或間接通過誘導(dǎo)供者抗原特異性調(diào)節(jié)性T細(xì)胞的生成、在體內(nèi)形成T細(xì)胞階聯(lián)效應(yīng)而抑制異基因T淋巴細(xì)胞的活化,因此研究PIR在樹突狀細(xì)胞的表達(dá)、T細(xì)胞階聯(lián)的關(guān)系及與免疫耐受的關(guān)系,可能為誘導(dǎo)供者M(jìn)HC特異性耐受,實(shí)現(xiàn)GVHD及GVL的分離提供新的途徑。 第一部分免疫球蛋白樣受體在小鼠樹突狀細(xì)胞上的表達(dá)及與免疫耐受關(guān)系的研究 目的配對(duì)的免疫球蛋白樣受體A、B(paired immunoglobulin-like receptor A、B, PIR-A、PIR-B)屬于小鼠免疫球蛋白超家族成員。研究配對(duì)免疫球蛋白樣受體PIR-A、B在小鼠DCs上的表達(dá)及與表面共刺激分子變化的關(guān)系,探討PIR與免疫耐受的關(guān)系,探索誘導(dǎo)耐受性DCs的有效途徑。 方法以C57BL/6小鼠來源DC系DC2.4細(xì)胞為研究對(duì)象,分別以重組小鼠白介素-10(recombinant mouse interleukin-10,rmIL-10)、重組人轉(zhuǎn)化生長因子β1 (recombinant human transforming growth factorβ1,rhTGF -β1)誘導(dǎo)DC2.4細(xì)胞為耐受性DC(tolerogenic DC,T-DC),脂多糖(LPS)刺激48h為成熟DC2.4細(xì)胞(LPS-DC),體外化學(xué)合成特異PIR-B小RNA干擾片段(small interfering RNA,siRNA),以Lip2000轉(zhuǎn)染DC2.4細(xì)胞(Si-DC)。分別應(yīng)用半定量RT-PCR、流式細(xì)胞儀(Flow cytometry, FCM)及Western blot檢測IL-10、TGF-β1、LPS及小干擾RNA對(duì)DC2.4細(xì)胞上PIR-A/B表達(dá)的影響;檢測LPS刺激Si-DCs后表面共刺激分子CD80、CD86、MHC-Ⅱ及PIR-A的變化;以2-△△Ct表示各目的基因cDNA轉(zhuǎn)錄的相對(duì)表達(dá)量。分別以上述各組DCs細(xì)胞為刺激細(xì)胞,以異基因BALB/c小鼠脾淋巴細(xì)胞為反應(yīng)細(xì)胞,應(yīng)用3H-TdR標(biāo)記法檢測同種異體淋巴細(xì)胞的增殖能力(MLR),ELISA方法測MLR上清中IFN-γ的分泌水平變化。 結(jié)果FCM檢測DC2.4細(xì)胞上PIR-A、PIR-B的共同的胞外區(qū)PIR表達(dá)的陽性率為(28.65±8.12)%,IL-10、TGF-β1及LPS誘導(dǎo)后PIR表達(dá)均上調(diào)(P0.05),分別為(54.21±6.34)%,(58.78±4.70)%,(48.24±6.75)%,但I(xiàn)L-10、TGF-β1及LPS各組間無顯著性差別(P0.05)。半定量RT-PCR及Western blot顯示,IL-10、TGF-β1誘導(dǎo)DC2.4細(xì)胞后PIR-B的mRNA及蛋白表達(dá)升高,而PIR-A表達(dá)則降低,而LPS刺激時(shí)則相反,PIR-A的mRNA及蛋白表達(dá)升高、PIR-B的表達(dá)則降低。流式細(xì)胞儀檢測SiRNA陽性對(duì)照組的轉(zhuǎn)染率為93.12%,SYBR greenⅠRealtime-PCR檢測,LPS刺激后Si-DCs CD80、CD86、MHC-Ⅱ及PIR-A的表達(dá)高于正常DCs組。LPS-DCs組CD80、CD86、MHC-Ⅱ及PIR-A的2-△△Ct分別為5.02±1.09、4.69±1.75、5.46±1.79、6.02±2.13;LPS刺激后Si-DC組TAI分別為8.79±2.2、11.03±1.96、10.26±2.55、12.10±2.83,同LPS刺激的正常組相比,Si-DC組分別增加了3.72、6.34、4.8、6.08倍(P0.05)�；旌狭馨图�(xì)胞反應(yīng)顯示:正常DC2.4細(xì)胞可刺激異基因淋巴細(xì)胞反應(yīng),IL-10、TGFβ1誘導(dǎo)的T-DC組MLR明顯受抑(P0.05),MLR上清中IFN-γ水平也相應(yīng)降低(P0.05)。LPS-DC及Si-DCs組MLR明顯增強(qiáng)(P0.05),MLR上清中IFN-γ水平明顯增高(P0.05); 結(jié)論上調(diào)免疫抑制性受體PIR-B、下調(diào)活化性受體PIR-A是小鼠DCs獲得耐受的普遍表型特征及分子生物學(xué)機(jī)制,沉默PIR-B的表達(dá)可使PIR-A及CD80、CD86、MHC--Ⅱ及PIR-A過表達(dá),使DCs活化的機(jī)制,PIR-A和PIR-B構(gòu)成了小鼠樹突狀細(xì)胞耐受的新靶點(diǎn)。 第二部分高度表達(dá)免疫球蛋白樣受體B耐受性樹突狀細(xì)胞可誘導(dǎo)CD4+CD25+調(diào)節(jié)性T細(xì)胞生成 目的研究配對(duì)免疫球蛋白樣受體B在樹突狀細(xì)胞上表達(dá)與調(diào)節(jié)性T細(xì)胞的生成的關(guān)系,探討耐受性DCs誘導(dǎo)耐受的詳細(xì)機(jī)制,為體內(nèi)誘導(dǎo)耐受性DCs及調(diào)節(jié)性T細(xì)胞(Treg)生成提供實(shí)驗(yàn)依據(jù)。 方法免疫磁珠分選BALB/c小鼠CD4+T脾淋巴細(xì)胞。以rmIL-10(50ng/ml)、rhTGF-β1(50ng/ml)聯(lián)合誘導(dǎo)C57BL/6小鼠來源的DC2.4細(xì)胞3天生成耐受性DCs(T-DC),同時(shí)設(shè)正常DC2.4細(xì)胞(DC)及LPS刺激48h后成熟的DC2.4細(xì)胞(mDC)干擾PIR-B組(Si-DCs)為對(duì)照組,各組DCs分別與BALB/c小鼠CD4+T脾淋巴細(xì)胞混合培養(yǎng)48h,檢測Treg生成。RT-PCR檢測轉(zhuǎn)錄因子Foxp3mRNA的表達(dá)變化,流式細(xì)胞儀檢測CD4+CD25+Treg細(xì)胞的比例,PI檢測CD4+T細(xì)胞的凋亡。磁珠分選的CD4+CD25+Treg與CD4+T細(xì)胞按照不同的比例加入MLR體系中,3H檢測Treg對(duì)異基因DCs刺激的同基因淋巴細(xì)胞的增殖能力影響。 結(jié)果磁珠分選BALB/c小鼠脾CD4+T及CD4+CD25+T淋巴細(xì)胞純度95%,正常DCs、T-DCs、Si-DC及mDCs各組細(xì)胞同BALB/c小鼠脾細(xì)胞CD4+T細(xì)胞混合培養(yǎng)3天,RT-PCR檢測表明,T-DCs組誘導(dǎo)后CD4+T細(xì)胞Foxp3mRNA表達(dá)明顯高于正常DCs、LPS-DC及Si-DC組。而Si-DC及LPS-DC刺激的CD4+T細(xì)胞Foxp3mRNA的表達(dá)明顯降低(P0.05)。流式細(xì)胞儀檢測表明,正常DCs、T-DCs、Si-DC及mDCs誘導(dǎo)的CD4+CD25+Treg細(xì)胞比例分別為(5.19±1.2)%、(28.29±2.36)%、(1.06±0.55) %,(2.01±0.66) %,以T-DC組誘導(dǎo)的Treg細(xì)胞比例明顯增高(P0.01)。PI檢測正常DCs、T-DCs、mDCs及Si-DC組誘導(dǎo)48h后CD4+T細(xì)胞的的凋亡率分別為(8.3±0.7)%、(21.56±2.32)%、(2.5±0.8)%、(1.9±0.7)%。3H檢測異基因混合淋巴細(xì)胞增殖反應(yīng)細(xì)胞刺激的增殖效應(yīng),且呈劑量依賴性。 結(jié)論誘導(dǎo)Treg細(xì)胞生成、促進(jìn)異基因淋巴細(xì)胞凋亡是PIR-B介導(dǎo)性DCs耐受的分子機(jī)制,為臨床應(yīng)用耐受性DCs誘導(dǎo)免疫耐受提供理論依據(jù),也為Treg的誘導(dǎo)提供新的途徑。 第三部分CD8+CD28-T細(xì)胞對(duì)小鼠樹突狀細(xì)胞上配對(duì)免疫球蛋白樣受體A和B表達(dá)的影響及與耐受的關(guān)系 目的誘導(dǎo)宿主產(chǎn)生供者主要組織相容性抗原的特異性耐受是臨床骨髓移植的最終目標(biāo),CD8 + CD28-T(Ts)細(xì)胞是具有免疫抑制作用的調(diào)節(jié)性T細(xì)胞亞群之一,體外誘導(dǎo)異基因抗原特異性Ts生成,以研究Ts細(xì)胞與小鼠樹突狀細(xì)胞(DCs)上配對(duì)免疫球蛋白樣受體A和B表達(dá)的關(guān)系,探討其誘導(dǎo)免疫耐受的分子機(jī)制及特點(diǎn),為臨床抗原特異性免疫治療的誘導(dǎo)提供理論基礎(chǔ)。 方法體外誘導(dǎo)Ⅰ類主要組織相容性抗原(H-2b)抗原特異性Ts細(xì)胞群,以C57BL/6小鼠(H-2b)骨髓來源的樹突狀細(xì)胞系DC2.4細(xì)胞為刺激細(xì)胞,同BALB/c小鼠(H-2d)脾淋巴細(xì)胞混合培養(yǎng),連續(xù)兩次,每次培養(yǎng)7天,第10天于培養(yǎng)體系中加入IL-2(10u/ml),第14天結(jié)束培養(yǎng)。以生物素標(biāo)記的CD28、CD8標(biāo)記上述細(xì)胞群,以鏈親和素標(biāo)記的免疫磁珠分兩步分選Ts細(xì)胞,首先負(fù)選CD8+T細(xì)胞,再正選CD28+T細(xì)胞,陰選細(xì)胞懸液為Ts細(xì)胞群。Ts同C57BL/6小鼠DC2.4(H-2b)細(xì)胞混合培養(yǎng)48h,RT-PCR檢測DCs細(xì)胞PIR-A、PIR-BmRNA的表達(dá),Westernblot檢測DCs細(xì)胞PIR-A、B的表達(dá)。3H標(biāo)記檢測混合淋巴細(xì)胞增殖反應(yīng)(MLR),體外誘導(dǎo)培養(yǎng)KM鼠骨髓來源的樹突狀細(xì)胞,分別以DC2.4(H-2b)及第三者主要組織相容性抗原無關(guān)的KM供鼠DCs細(xì)胞為刺激細(xì)胞,以BALB/c小鼠來源的脾CD4+T淋巴細(xì)胞為反應(yīng)細(xì)胞,加入Ts細(xì)胞,以CPM檢測異基因淋巴細(xì)胞增殖反應(yīng)能力。 結(jié)果體外以C57BL/6小鼠DCs誘導(dǎo)并在體外應(yīng)用免疫磁珠分選的CD8+、CD8+CD28-Ts 90%,以BALB/c小鼠Ts細(xì)胞(H-2d)與異基因C57BL/6小鼠DCs細(xì)胞(H-2b)混合培養(yǎng)48h后,RT-PCR及Western blot檢測PIR-BmRNA及蛋白表達(dá)上調(diào)、PIR-A的mRNA及蛋白表達(dá)則下調(diào)。3H摻入標(biāo)記檢測顯示,DC2.4細(xì)胞及KM鼠DCs細(xì)胞均可刺激BALB/c小鼠(H-2d)脾CD4+T淋巴細(xì)胞增殖,加入Ts細(xì)胞后,可以明顯抑制DC2.4細(xì)胞刺激的BALB/c小鼠脾CD4+T淋巴細(xì)胞(H-2d)的增殖,而并不抑制KM鼠DCs細(xì)胞刺激的CD4+T脾淋巴細(xì)胞(H-2k)的增殖反應(yīng)。 結(jié)論體外誘導(dǎo)的Ts呈現(xiàn)Ⅰ類主要組織相容性抗原特異性抑制異基因反應(yīng)性淋巴細(xì)胞的增殖。其機(jī)制與Ts細(xì)胞上調(diào)PIR-B mRNA、下調(diào)PIR-A mRNA的表達(dá)有關(guān)。升高供體移植物中抗原特異性Ts細(xì)胞比例或受體樹突狀細(xì)胞表面免疫抑制性受體的表達(dá)可能成為誘導(dǎo)受者產(chǎn)生針對(duì)供體抗原特異性免疫耐受的有效途徑。
[Abstract]:Graft-versus-host disease (GVHD) is still one of the major obstacles in the treatment of malignant diseases of the blood system in clinical bone marrow transplantation. Abnormal activation of allogeneic lymphocytes in donors is an important factor in the development of GVHD. It is the most important factor to induce the recipient to produce MHC specific tolerance against donor allogeneic major histocompatibility (MHC), which is the most important factor to prevent GVHD and to preserve GVL Paired immunoglobin-like receptor (PIR) is an immunosuppressive receptor that is mainly expressed in mouse dendritic cells (DCs), including immunosuppressive receptor (PIR-B) and immune activation receptor (PIR-A). The ligand of the ligand are MHC- I, the level of the binding of two to its ligand. It is one of the important molecular markers to determine the degree of immune activation of DCs. Because DC is not only the key to regulate the activation of T cells in the body, it is also an ideal target cell for inducing immune tolerance. It can directly or indirectly induce the generation of donor antigen specific regulatory T cells and form the order of T cells in the body to inhibit T lymphatic fining of the allogenic T. Therefore, the study of the expression of PIR in dendritic cells, the relationship of T cell order and the relationship with immune tolerance may provide a new way for inducing MHC specific tolerance and the separation of GVHD and GVL.
The first part is the expression of immunoglobulin like receptor on mouse dendritic cells and its relationship with immune tolerance.
Objective the paired immunoglobulin like receptor A, B (paired immunoglobulin-like receptor A, B, PIR-A, PIR-B) belong to the members of the mouse immunoglobulin superfamily. The relationship between the expression of paired immunoglobulin like receptor PIR-A, B on mice DCs and the changes in the surface costimulatory molecules, and the relationship between the immune tolerance and the immune tolerance are explored to explore the induction of tolerance. An effective way of being subjected to sexual DCs.
Methods the DC DC2.4 cells from C57BL/6 mice were used as the research object, and the recombinant human interleukin -10 (recombinant mouse interleukin-10, rmIL-10) and recombinant human transforming growth factor beta 1 (recombinant human transforming growth) were induced. 48h is a mature DC2.4 cell (LPS-DC), and the specific PIR-B small RNA interference fragment (small interfering RNA, siRNA) is synthesized in vitro (small interfering RNA, siRNA), and Lip2000 transfected to DC2.4 cells (Si-DC). The changes in the surface CO stimulatory molecules CD80, CD86, MHC- II and PIR-A were detected after LPS stimulation of Si-DCs, and the relative expression of cDNA transcript of each target gene was expressed with 2- Delta Delta Ct. The DCs cells in all of the above-mentioned groups were stimulated cells and the spleen lymphocytes of heterologous BALB/c mice were used as reactive cells, and the lymphatic allograft was detected by 3H-TdR labeling method. Cell proliferation ability (MLR), ELISA method was used to measure the secretion level of IFN- IFN- in supernatant.
Results FCM detected PIR-A on DC2.4 cells and the positive rate of PIR expression in the common extracellular domain of PIR-B was (28.65 + 8.12)%, IL-10, TGF- beta 1 and LPS induced PIR expression up up (P0.05), respectively (54.21 + 6.34)%, (58.78 + 4.70)%, (48.24 + 6.75)%, but IL-10, TGF- beta 1 and each group showed no significant difference. The expression of mRNA and protein in PIR-B was increased after DC2.4 cells were induced by IL-10 and TGF- beta 1, but the expression of PIR-A decreased, while LPS stimulation was the opposite, the mRNA and protein expression of PIR-A were increased and the expression of PIR-B decreased. The transfection rate of SiRNA positive control group was 93.12%. 86, the expression of MHC- II and PIR-A is higher than that of the normal DCs group.LPS-DCs group CD80, CD86, MHC- II and PIR-A's 2- Delta Delta Ct are 5.02 + 1.09,4.69 + + + 2.13 respectively. P0.05. The mixed lymphocyte reaction showed that normal DC2.4 cells could stimulate the reaction of allogeneic lymphocytes. The MLR in T-DC group induced by IL-10, TGF beta 1 was obviously inhibited (P0.05), and the level of IFN- gamma in MLR supernatant was also decreased (P0.05).LPS-DC and Si-DCs group increased significantly.
Conclusion up regulation of immunosuppressive receptor PIR-B and down-regulation of activated receptor PIR-A are the universal phenotypic characteristics and molecular biological mechanism of DCs tolerance in mice. The expression of silent PIR-B can make PIR-A and CD80, CD86, MHC-- II and PIR-A overexpressed. The mechanism of DCs activation, PIR-A and PIR-B are the new targets of mouse dendritic cell tolerance.
The second part of the highly expressed immunoglobulin like receptor B tolerant dendritic cells can induce the formation of CD4+CD25+ regulatory T cells.
Objective to study the relationship between the expression of paired immunoglobulin like receptor B and the production of regulatory T cells in dendritic cells, and to explore the detailed mechanism of tolerance induced tolerance of DCs, and to provide experimental basis for inducing tolerance DCs and regulatory T cells (Treg) in vivo.
The CD4+T splenic lymphocyte of BALB/c mice was selected by immunomagnetic beads. The DC2.4 cells derived from C57BL/6 mice were combined with rmIL-10 (50ng/ml) and rhTGF- beta 1 (50ng/ml) to induce the tolerance DCs (T-DC). The CD4+T splenic lymphocyte of /c mice was mixed with 48h, and the expression of Foxp3mRNA was detected by Treg generation.RT-PCR. The proportion of CD4+CD25+Treg cells was detected by flow cytometry. PI was used to detect the apoptosis of CD4+T cells. The CD4+CD25+Treg of magnetic beads and CD4+T cells were added to the MLR system according to the different specific cases. Stimulation of the proliferation ability of syngeneic lymphocytes.
Results the purity of CD4+T and CD4+CD25+T lymphocytes in the spleen of BALB/c mice was 95%. The cells of normal DCs, T-DCs, Si-DC and mDCs were mixed with the CD4+T cells of the spleen cells of BALB/c mice for 3 days. The RT-PCR detection showed that the expression of CD4+T cells was obviously higher than that of the normal group after the T-DCs group. The expression of Foxp3mRNA was significantly reduced (P0.05). Flow cytometry showed that the proportion of normal DCs, T-DCs, Si-DC and mDCs induced CD4+CD25+Treg cells was (5.19 + 1.2)%, (28.29 + 2.36)%, (1.06 + 0.55)%, (2.01 + 0.66)%, and the proportion of Treg cells induced by T-DC group was significantly higher (P0.01).PI detection of normal DCs. The apoptosis rate of CD4+T cells was (8.3 + 0.7)%, (21.56 + 2.32)%, (2.5 + 0.8)%, (1.9 + 0.7)%.3H, respectively, and (1.9 + 0.7)%.3H to detect the proliferation effect of allogeneic mixed lymphocyte proliferation reaction, and it was dose-dependent.
Conclusion induction of Treg cell production and promoting the apoptosis of allogeneic lymphocytes is the molecular mechanism of PIR-B mediated DCs tolerance, providing a theoretical basis for the clinical application of tolerance DCs to induce immune tolerance, and also provides a new way for the induction of Treg.
The third part is the effect of CD8+CD28-T cells on the expression of paired immunoglobulin like receptors A and B in mouse dendritic cells and their relationship with tolerance.
CD8 + CD28-T (Ts) cells are one of the regulatory T cell subsets with immunosuppressive effects, and the specific Ts generation of allogenic antigen in vitro can be induced in vitro, in order to study the paired immunity of Ts cells and mouse dendritic cells (DCs). The relationship between the expression of globulin like receptor A and B and the molecular mechanism and characteristics of its induced immune tolerance provide a theoretical basis for the induction of clinical antigen specific immunotherapy.
Methods the primary histocompatibility antigen (H-2b) antigen specific Ts cell group was induced in vitro. The dendritic cell line DC2.4 cells derived from C57BL/6 mice (H-2b) were used as stimulating cells and mixed culture with BALB/c mice (H-2d) splenic lymphocytes for two consecutive times, each time was 7 days, and IL-2 (10u/ml) was added to the culture system for tenth days and fourteenth days. At the end of the culture, CD28, CD8 labeled with biotin, were labeled with the above cell group, and the Ts cells were divided into two steps with the immunomagnetic beads labeled by streptavidin. First, the CD8+T cells were selected, and then the CD28+T cells were selected, the Ts cell group.Ts was mixed with the DC2.4 (H-2b) cells of the C57BL/6 mice, and the RT-PCR detected the expression of the cells. Westernblot detection of DCs cells PIR-A, B expression.3H markers to detect mixed lymphocyte proliferation response (MLR), and in vitro induction and culture of dendritic cells from the bone marrow of KM mice. DC2.4 (H-2b) and KM of the three main histocompatibility antigen independent KM mouse DCs cells are prickly cells. Ts cells were added into the cells, and the ability of allogeneic lymphocyte proliferation was detected by CPM.
Results in vitro, CD8+, CD8+CD28-Ts 90%, was induced by DCs in C57BL/6 mice and used in vitro by immunomagnetic beads. BALB/c mice Ts cells (H-2d) were mixed with DCs cells (H-2b) in C57BL/6 mice. The results showed that DC2.4 cells and KM mouse DCs cells stimulated the proliferation of CD4+T lymphocytes in the spleen of BALB/c mice (H-2d). After adding Ts cells, the proliferation of the spleen CD4+T lymphocyte (H-2d) of BALB/c mice stimulated by DC2.4 cells was obviously inhibited, but the proliferation reaction of spleen lymphocyte stimulated by KM mouse cells was not inhibited.
Conclusion Ts in vitro induced the proliferation of the main histocompatibility antigen specific inhibition of allogeneic reactive lymphocytes. The mechanism is related to the up regulation of PIR-B mRNA, down regulation of the expression of PIR-A mRNA, the increase of the proportion of antigen specific Ts cells in donor grafts or the expression of immunosuppressive receptors on the surface of the receptor tree process cells. It may be an effective way to induce recipient to produce donor specific antigen tolerance.
【學(xué)位授予單位】：華中科技大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2007
【分類號(hào)】：R392

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 盤鷹;張錦X;;樹突狀細(xì)胞介導(dǎo)的腫瘤基因免疫治療[J];癌變.畸變.突變;2006年06期

2 史泓瀏;陳忠平;;樹突狀細(xì)胞疫苗治療腦膠質(zhì)瘤的研究進(jìn)展[J];中國神經(jīng)腫瘤雜志;2004年01期

3 張雪;林敬明;姜曉丹;馬宏偉;秦琨;郭愛林;劉煜;;人CD80基因轉(zhuǎn)染U251瘤株細(xì)胞的實(shí)驗(yàn)研究[J];中華神經(jīng)醫(yī)學(xué)雜志;2007年04期

4 王東海,李新鋼,鮑修風(fēng);膠質(zhì)瘤樹突狀細(xì)胞疫苗研究進(jìn)展[J];國外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));2004年05期

5 李春暉,張慶九,焦保華;樹突狀細(xì)胞在腦膠質(zhì)瘤治療中的應(yīng)用[J];河北醫(yī)藥;2004年02期

6 張路遙;鞠硯;;膠質(zhì)瘤免疫治療新進(jìn)展[J];吉林醫(yī)學(xué);2007年02期

7 劉崢嶸;黎緯明;張敏;周浩;韓紅;鄒萍;;Paired Immunoglobin-like Receptors A and B Are New Targets for Inducing Dendritic Cells Tolerance in Mice[J];Journal of Huazhong University of Science and Technology(Medical Sciences);2007年03期

8 Terence Moyana;Jim Xiang;;Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors[J];Cell Research;2006年03期

9 劉崢嶸;張敏;黎緯明;周浩;鄒萍;;IL-10誘導(dǎo)小鼠樹突狀細(xì)胞耐受的分子機(jī)制[J];中國病理生理雜志;2008年02期

10 牛洪泉,董震,董芳永,張韜,雷霆,薛德麟;樹突狀細(xì)胞和腦膠質(zhì)瘤自體免疫治療的實(shí)驗(yàn)和臨床研究(英文)[J];The Chinese-German Journal of Clinical Oncology;2004年03期

相關(guān)博士學(xué)位論文 前10條

1 張義;抑制性受體ILTs及其配體在胃癌表達(dá)的實(shí)驗(yàn)和臨床研究[D];山東大學(xué);2010年

2 宮安靜;腫瘤干細(xì)胞致敏的樹突狀細(xì)胞對(duì)腦膠質(zhì)瘤免疫作用研究[D];山東大學(xué);2011年

3 潘建平;γ-干擾素對(duì)樹突狀細(xì)胞分化和功能成熟的調(diào)控及其基因修飾的樹突狀細(xì)胞抗腫瘤免疫機(jī)制研究[D];浙江大學(xué);2002年

4 李楠;人樹突狀細(xì)胞來源的新分子Siglec-10和人骨髓基質(zhì)細(xì)胞來源的新分子PHDP的克隆與功能研究[D];第二軍醫(yī)大學(xué);2002年

5 潘興華;廣東漢族人群殺傷細(xì)胞抑制性受體P58識(shí)別HLA-C的分子基礎(chǔ)研究[D];第一軍醫(yī)大學(xué);2002年

6 吳安華;膠質(zhì)瘤特異性肽疫苗相關(guān)肽及膠質(zhì)瘤特異性啟動(dòng)子的鑒定[D];中國醫(yī)科大學(xué);2003年

7 王東海;DC/C6融合瘤苗防治大鼠C6膠質(zhì)瘤的實(shí)驗(yàn)研究[D];山東大學(xué);2005年

8 付玉;IFN-α基因修飾樹突狀細(xì)胞抗神經(jīng)膠質(zhì)瘤及其機(jī)制的研究[D];吉林大學(xué);2006年

9 徐剛;人IgA Fc受體FcαRI（CD89）的結(jié)構(gòu)和功能分析[D];中國協(xié)和醫(yī)科大學(xué);2004年

10 盤鷹;負(fù)載EBV-LMP2基因人樹突狀細(xì)胞疫苗的制備及抗腫瘤免疫研究[D];汕頭大學(xué);2006年

相關(guān)碩士學(xué)位論文 前8條

1 宮安靜;樹突狀細(xì)胞誘導(dǎo)的CTL對(duì)神經(jīng)膠質(zhì)瘤細(xì)胞的體外殺傷作用研究[D];青島大學(xué);2004年

2 李春暉;樹突狀細(xì)胞瘤苗抗腦膠質(zhì)瘤作用的體外實(shí)驗(yàn)研究[D];河北醫(yī)科大學(xué);2004年

3 陳澤欽;人正常腦組織和腦膠質(zhì)瘤中樹突狀細(xì)胞免疫功能的研究[D];汕頭大學(xué);2004年

4 史進(jìn);HSP70腫瘤肽復(fù)合物抗膠質(zhì)瘤免疫效應(yīng)的研究[D];昆明醫(yī)學(xué)院;2006年

5 張雪;GPI-CD80表達(dá)載體的構(gòu)建、在COS-7細(xì)胞的表達(dá)及其錨定功能的初步研究[D];南方醫(yī)科大學(xué);2007年

6 楊恒麗;小鼠樹突狀細(xì)胞TLR7表達(dá)及其介導(dǎo)的免疫應(yīng)答初步研究[D];第四軍醫(yī)大學(xué);2008年

7 王高燕;卡介菌多糖核酸對(duì)白血病兒童樹突狀細(xì)胞誘導(dǎo)的抗白血病作用的影響[D];青島大學(xué);2010年

8 李春云;特異性CTL對(duì)移植性小鼠神經(jīng)膠質(zhì)瘤免疫治療的研究[D];河北師范大學(xué);2012年

，

本文編號(hào)：2128714